Associate Scientist / Scientist – Target Validation / Molecular and Cell biology

Storm Therapeutics Ltd

Closing Date: 30/06/2022

Associate Scientist / Scientist – Target Validation / Molecular and Cell biology

Storm Therapeutics is a small drug discovery company based at Babraham Research Campus near Cambridge UK, working in the emerging field of RNA epigenetics. We are now looking to recruit two enthusiastic and talented molecular or cell biologists.

This will be a tremendous opportunity for early-stage career scientists to join a dynamic biotech company and to contribute to our understanding of RNA modifications in cancer and other diseases. In this role, the successful applicants will work in a team of experienced researchers to support the drug discovery process across multiple projects. Day-to-day activities may involve testing novel pharmacological inhibitors in tissue culture cells, using siRNA or CRISPR methods to manipulate target gene expression, analysing putative protein or RNA biomarkers, and preparing RNA for subsequent modification and transcriptomics analyses.

The two positions are available at the Associate Scientist or Scientist level depending on experience and qualifications.

STORM Therapeutics offers an industry-competitive salary and benefits package, exciting science, and a great place to work.

Qualifications and skills required

Essential qualifications and skills for the posts:

• BSc/MSc in a relevant life science subject such as Biology or Biochemistry

• Good molecular biology and cell biology background.

• Hands-on experience with standard molecular biology methods such as DNA/RNA extractions, PCR, gel electrophoresis, western blotting.

• Experience with tissue culture maintenance and working with cancer cell lines.

• Ability to work independently and as part of a team.

• Organised approach to work and excellent time management skills.

• Candidates must be legally entitled to work in the UK.

Desirable additional skills:

• Practical laboratory experience in addition to university courses, e.g. placement year, BSc/MSc project in academic lab.

• Experience with RNA-related molecular biology methods, for example qRT-PCR.

• Hands-on experience with a wider range of tissue culture methods, such as plasmid or siRNA transfections, CRISPR-based methods.

• Experience with cellular assays and cell-based methods such as immunofluorescence.

• Knowledge of cancer biology.

About Storm Therapeutics

STORM Therapeutics is a University of Cambridge spin-out, translating the ground-breaking work of Professors Tony Kouzarides and Eric Miska in RNA epigenetics into the discovery of first-in-class drugs in oncology and other diseases. It is the leading company tackling cancer through the modulation of RNA modifying enzymes, including RNA methyltransferases, exemplified by the development of a first-in-class METTL3 inhibitor (Yankova et al., Nature 2021). STORM has developed a unique platform to pioneer drug development in this new field and established a pipeline of projects, aiming to take them to the clinic.

STORM is backed by blue chip investors Cambridge Innovation Capital, Merck Ventures, Pfizer Ventures, Taiho Ventures LLC, IP Group and Seroba Life Sciences who share the founders’ ambitions to build a world-leading company in the field. The company occupies modern, well-equipped laboratories on the Babraham Research Campus near Cambridge.

Please apply to: with a CV and covering letter, indicating where you heard about the job advert.

The closing date for applications is the 30th June 2022, but applications will be reviewed on a rolling basis and will be held in accordance with our GDPR Job Applicant Policy

Candidates must be legally entitled to work in the UK.